Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (1) , 27-36
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (1R33CA196458)
This publication has 24 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancerOncogene, 2011
- C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab TrialJournal of Clinical Oncology, 2011
- The Ability of Biomarkers to Predict Systemic Progression in Men with High-Risk Prostate Cancer Treated Surgically Is Dependent on ERG StatusCancer Research, 2010
- Multiple loci on 8q24 associated with prostate cancer susceptibilityNature Genetics, 2009
- ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer MetastasisCancer Research, 2008
- Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancerNature, 2007
- Genetic aberrations in prostate cancer by microarray analysisInternational Journal of Cancer, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Evaluation of genetic patterns in different tumor areas of intermediate‐grade prostatic adenocarcinomas by high‐resolution genomic array analysisGenes, Chromosomes and Cancer, 2004